Eliezer VanAllen

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).

Sara M. Tolaney, Romualdo Barroso‐Sousa, Tanya E. Keenan et al. · Journal of Clinical Oncology · 2019 · 26 citations

Medicine, Oncology, Pharmacology +17

Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).

Rana R. McKay, Bradley A. McGregor, Kathryn P. Gray et al. · Journal of Clinical Oncology · 2019 · 25 citations

Medicine, Oncology, Pharmacotherapy +14

Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).

Martin H. Voss, Jacqueline L. Buros, Matthew D. Hellmann et al. · Journal of Clinical Oncology · 2018 · 21 citations

Medicine, Immunology, Oncology +17

Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab.

Martin H. Voss, Matthew D. Hellmann, Ying‐Bei Chen et al. · Journal of Clinical Oncology · 2016 · 13 citations

Medicine, Genetics, Oncology +17

Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC).

Rana R. McKay, Dylan J. Martini, Raphael Brandão Moreira et al. · Journal of Clinical Oncology · 2017 · 10 citations

Medicine, Oncology, Pharmacology +17